Clinical trial
DESolve Post-Approval Study
NCT02013349 · Elixir Medical Corporation, Industry · Completed
Key facts
| NCT number | NCT02013349 |
|---|---|
| Title | DESolve Post-Approval Study |
| Official title | POST-MARKET EVALUATION OF DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS |
| Lead sponsor | Elixir Medical Corporation, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Device |
| Interventions | coronary intervention |
| Enrollment | 102 |
| Start date | Apr 22, 2014 |
| Primary completion | Oct 1, 2015 |
| Completion | Apr 1, 2019 |
| First posted | Dec 17, 2013 |
| Last update posted | Apr 8, 2020 |
| Countries | Germany, Italy, Jordan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: